Table 2.
Summary of P. vivax recurrences with probabilistic estimates of recurrence states derived from the time-to-event model.
| Treatment | Recurrences (patient follow-up years) | Relapsea | Recrudescencea | Reinfectiona |
|---|---|---|---|---|
| Artesunate monotherapy | 722 (161) | 96.1 (94.3–97.3) | 0.3 (0.2–0.5) | 3.6 (2.4–5.5) |
| Chloroquine monotherapy | 587 (169) | 95.0 (92.9–96.6) | 0.2 (0.1–0.4) | 4.8 (3.3–6.9) |
| *Primaquine+b | 132 (677) | 12.2 (9.3–15.9) | 0.01 (0.01–0.02) | 87.7 (84.1–90.7) |
| VHX: *Primaquine+ | 40 (155) | 9.2 (6.4–12.2) | 0.03 (0.01–0.06) | 90.8 (87.8–93.6) |
| BPD: *Primaquine+ | 92 (522) | 13.5 (10.1–17.3) | 0.01 (0–0.01) | 86.5 (82.7–89.9) |
*Primaquine+ refers to the radical cure combination treatment of primaquine together with one of two blood-stage treatments: chloroquine or dihydroartemisinin-piperaquine
aProbabilistic breakdown of recurrences: mean probabilities (95% CI) estimated under the time-to-event model. All estimates have been rounded up to one decimal place and are expressed as percentages
bVHX and BPD studies combined